66 related articles for article (PubMed ID: 35567430)
1. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis.
Agnello L; Vidali M; Giglio RV; Gambino CM; Ciaccio AM; Lo Sasso B; Ciaccio M
Clin Chem Lab Med; 2022 Jul; 60(8):1261-1277. PubMed ID: 35567430
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.
Wang W; Wang M; Wang L; Adams TS; Tian Y; Xu J
Sci Rep; 2014 May; 4():5012. PubMed ID: 24852453
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds.
Kawada T; Shim SR; Quhal F; Rajwa P; Pradere B; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
Eur Urol Oncol; 2023 Nov; ():. PubMed ID: 37981495
[TBL] [Abstract][Full Text] [Related]
4. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
[No Abstract] [Full Text] [Related]
5. Diagnostic accuracy of multiparametric ultrasound in the diagnosis of prostate cancer: systematic review and meta-analysis.
Tang Y; Li X; Jiang Q; Zhai L
Insights Imaging; 2023 Nov; 14(1):203. PubMed ID: 38001351
[TBL] [Abstract][Full Text] [Related]
6. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
Bergengren O; Pekala KR; Matsoukas K; Fainberg J; Mungovan SF; Bratt O; Bray F; Brawley O; Luckenbaugh AN; Mucci L; Morgan TM; Carlsson SV
Eur Urol; 2023 Aug; 84(2):191-206. PubMed ID: 37202314
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for detecting prostate cancer: Protocol for an umbrella review with integrated network meta-analysis.
Jia J; Sun Y; Ren J; Li M; Wang J; Li H;
Medicine (Baltimore); 2019 Jul; 98(30):e16517. PubMed ID: 31348264
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer: Novel genetic and immunologic biomarkers.
Samare-Najaf M; Kouchaki H; Moein Mahini S; Saberi Rounkian M; Tavakoli Y; Samareh A; Karim Azadbakht M; Jamali N
Clin Chim Acta; 2024 Mar; 555():117824. PubMed ID: 38316287
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of p2PSA and its derivatives (%p2PSA and Phi) in the diagnosis of prostate cancer.
Cai W; Xu H; Shi Y
Asian J Surg; 2023 Nov; 46(11):4922-4923. PubMed ID: 37328370
[No Abstract] [Full Text] [Related]
10. Extracellular vesicle biomarkers for prostate cancer diagnosis: A systematic review and meta-analysis.
Li Y; Shi X; Jia E; Qin S; Yu F
Urol Oncol; 2023 Nov; 41(11):440-453. PubMed ID: 37914569
[TBL] [Abstract][Full Text] [Related]
11. RAGE as a Novel Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis.
Applegate CC; Nelappana MB; Nielsen EA; Kalinowski L; Dobrucki IT; Dobrucki LW
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835583
[TBL] [Abstract][Full Text] [Related]
12. Prostate tumor markers: diagnosis, prognosis and management.
Lawisch GKDS; Dexheimer GM; Biolchi V; Seewald RA; Chies JAB
Genet Mol Biol; 2024; 46(3 Suppl 1):e20230136. PubMed ID: 38407310
[TBL] [Abstract][Full Text] [Related]
13. Modern biomarkers in prostate cancer diagnosis.
Porzycki P; Ciszkowicz E
Cent European J Urol; 2020; 73(3):300-306. PubMed ID: 33133657
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Prostate Cancer: From Diagnosis to Treatment.
Chen JY; Wang PY; Liu MZ; Lyu F; Ma MW; Ren XY; Gao XS
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958246
[TBL] [Abstract][Full Text] [Related]
15. An Update on Biochemical and Genomic Markers for Prostate Cancer.
Falahatkar R; Mokhtari G; Momeni-Moghaddam M; Teimoori M; Baghani Aal H; Akhavan A; Falahatkar S; Esmaeili S
Urol J; 2021 Nov; ():. PubMed ID: 34773635
[TBL] [Abstract][Full Text] [Related]
16. Could Reducing Body Fatness Reduce the Risk of Aggressive Prostate Cancer via the Insulin Signalling Pathway? A Systematic Review of the Mechanistic Pathway.
James R; Dimopoulou O; Martin RM; Perks CM; Kelly C; Mathias L; Brugger S; Higgins JPT; Lewis SJ
Metabolites; 2021 Oct; 11(11):. PubMed ID: 34822385
[TBL] [Abstract][Full Text] [Related]
17. Re: Russo GI, Regis F, Castelli T, et al. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. Clin Genitourin Cancer 2017; 15:429-39.
Zappala SM; Dong Y
Clin Genitourin Cancer; 2017 Aug; ():. PubMed ID: 29074283
[No Abstract] [Full Text] [Related]
18. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract][Full Text] [Related]
19. Clinical Biofluid Assays for Prostate Cancer.
Borbiev T; Kohaar I; Petrovics G
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201592
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
